The vaccination specialist is about to become popular

THE PREMIUM SERVICE FOR SUBSCRIBERS OF VALUE-DEPESCHE - August 23rd 2021

Defence Therapeutics

The vaccination specialist is about to become popular

The biotech company is developing vaccines against cancer and Corona. A vaccine against cancer is expected to be launched in late 2022, and one against Corona in early 2023. The share is about to become popular.

Since Biontech and Moderna with their novel vaccines against viruses, cancer has also come back into focus. The two companies now also want to develop a vaccine against cancer and this is boosting their share price. What about Covid-19 18 months ago? At that time, the two biotech companies were on the hook to develop a vaccine against the virus and after announcing these activities, their shares went through the roof within a few weeks or within two or three months. The mere fact of "developing a vaccine against Covid" brought the two stocks an increase in price of + 100 % and more in a short time. Even before the price surge, Biontech and Moderna were companies with market values of EUR 5.0 and 10.0 billion respectively.

As announced a week ago, I have now unearthed another promising player from that sector for you. Unlike Biontech and Moderna, however, with valuations in the billions even before the market launch of a Covid vaccine and the announcement of its development, this company is only worth EUR 165 million on the stock market.

"For the time being" is all I can say. Because my review of Defence Therapeutics has tremendous prospects! I expect the share price to multiply within the next two years!

I expect the share price to exceed 10 euros by 2022 at the latest!

The Vancouver biotech company is working not only on vaccines against infectious diseases and viruses, but also on a vaccine against cancer and against Covid-19.

Defence Therapeutics works with a specially developed platform to potentiate treatment options, for example against cancer, using ADC antibody-drug conjugates. Compared to conventional cancer treatments using chemotherapy and radiation these ADCs have low side effects and act very specifically against a tumor. ADCs consist of a highly potent toxin that is coupled with an antibody and, when administered, is absorbed by a tumor cell which is then killed by the toxin in the ADC.

The technology developed by Defence increases the active ingredient of the ADC by a factor of ten in some cases. The technology has already been successfully tested on mice and various studies in the approval process with the US Food and Drug Administration (FDA) are scheduled for the coming months and quarters.

Well-informed quarters assume that Defence will launch its first vaccine against cancer by the end of 2022. Defence's platform, together with the corresponding ADC-based drugs, can be used to develop new active substances relatively easily and quickly, but also compounds against a wide range of other diseases.

Industry experts believe that Defence will have a total of five compounds, for various types of cancer and infectious diseases, on the market by 2025, i.e. in four years' time.

That's not all. I have heard from well-informed sources that the Canadians are working at high speed to develop a vaccine against Corona. Well-informed sources are 100% sure that Defence will successfully launch a vaccine on the market. This should be as early as the first half of 2023, possibly as early as the beginning of the year.

Conclusion: I see a similar development coming for Defence as for Biontec and Moderna. In just a few years, the company could become a billion-dollar corporation. If further development successes are achieved with the first cancer drug or the vaccination against Corona, a licensing partnership with a large pharmaceutical company or even a takeover could be possible. In the case of a licensing partnership, I believe upfront payments for Defence of several hundred million dollars are possible as early as next year. In the event of a takeover, far more could be paid. In the next two to three years, I expect Defence to have a market capitalization of more than EUR 1.0 billion euros. Today it is EUR 165 million. A clear buy for all risk-loving investors

Risk notice/disclaimer/transparency notice/other:

All information provided in this newsletter has been carefully researched and comes from sources we believe to be reliable. Nevertheless, even the editors may be subject to misinformation or incorrect information may arise from other circumstances. All information is therefore provided without warranty. Liability for lost profits or other financial losses is therefore excluded. Good results in the past do not guarantee positive results in the future. This also explicitly applies to any form of share transactions, in particular option and warrant transactions: Shares, options and certificates are subject to various influencing factors. Therefore, it is pointed out that the investment in shares, options, etc. involves speculative risks which, depending on the development of the influencing factors, may lead to losses, in the worst case even to a total loss.

It is expressly advised against spreading investment funds over only a few investments or taking out loans for this purpose. As a precaution, we draw your attention to the fact that the editorial reviews in VALUE-DEPESCHE cannot replace individual investment advice from your investment advisor or investment consultant. The reviews are addressed to all subscribers/subscribers and readers of our stock letter, who are very different in their investment behavior and investment objectives. Therefore, the reviews of this stock letter do not take into account your personal investment situation in any way. The investments discussed in VALUE- DEPESCHE are for information purposes only and do not constitute an invitation to buy or sell securities.

Members of the editorial team advise investment products. The securities discussed in VALUE-DEPESCHE or Hot Stock are part of the investment universe of the product. Members of the editorial staff, their affiliates or related parties may hold a long or short position of securities described in VALUE-DEPESCHE publications and/or options, futures and other derivatives based on those securities, or other investments related to information published in the articles. Members of the editorial staff may advise or have advised the companies mentioned in the articles or may have a business relationship of some other kind.

Despite careful control of the content, we assume no liability for the content of external links. The operators of the linked pages are solely responsible for their content.

Subscription and cancellation

Subscription to Value-Depesche costs EUR 420 (CHF 450) for an annual subscription and EUR 280 (CHF 300) for a semi-annual subscription. Hot Stock, exclusively for VALUE-DEPESCHE subscribers, costs EUR 325 (CHF 340). If the service is not cancelled in writing up to three months before the end of the subscription period (the easiest way is to send an e-mail to: leserbrief@value- depesche.ch), the subscription is extended by the last agreed subscription period of one year or six months at the then current regular subscription price.

Copyright as well as all publishing rights and copyrights to "Value-Depesche" and Hot Stock are held by Georg Pröbstl. Reprints and copies, including excerpts, only with the written consent of the editors.

Charts courtesy of vwd-group (www.vwd.com)

Data protection: Information on data protection can be found at http://value- depesche.ch/content/impress

Defence Therapeutics (QB) (USOTC:DTCFF)
Historical Stock Chart
From Mar 2024 to Apr 2024